[go: up one dir, main page]

BR9910327A - Antibody, use of an antibody, DNA sequence encoding an antibody chain, and, pharmaceutical formulation - Google Patents

Antibody, use of an antibody, DNA sequence encoding an antibody chain, and, pharmaceutical formulation

Info

Publication number
BR9910327A
BR9910327A BR9910327-3A BR9910327A BR9910327A BR 9910327 A BR9910327 A BR 9910327A BR 9910327 A BR9910327 A BR 9910327A BR 9910327 A BR9910327 A BR 9910327A
Authority
BR
Brazil
Prior art keywords
antibody
antibodies
sequence encoding
dna sequence
pharmaceutical formulation
Prior art date
Application number
BR9910327-3A
Other languages
Portuguese (pt)
Inventor
Jean-Yves Marcel Paul Bonnefoy
Scott James Crowe
Jonathan Henry Ellis
Nicholas Timothy Rapson
Jean Shearin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9910327A publication Critical patent/BR9910327A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPO, USO DE UM ANTICORPO, SEQuêNCIA DE DNA CODIFICANDO UMA CADEIA DE ANTICORPO, E, FORMULAçãO FARMACêUTICA" A invenção refere-se a anticorpos que se ligam à molécula CD23 (FC<sym>RII) de tipo II, particularmente a anticorpos alterados incluindo anticorpos que se ligam à molécula CD23 (FC<sym>RII) de tipo II caracterizados por uma constante de afinidade igual ou maior que 1 x 10^ 9^ Ka Mol^ -1^, à preparação desses anticorpos, a composições farmacêuticas que contêm esses anticorpos, e a seu uso na terapia, particularmente no tratamento de distúrbios autoimunes e inflamatórios."ANTIBODY, USE OF AN ANTIBODY, DNA SEQUENCE ENCODING AN ANTIBODY CHAIN, AND, PHARMACEUTICAL FORMULATION" The invention relates to antibodies that bind to the type II CD23 (FC <sym> RII) molecule, particularly altered antibodies including antibodies that bind to the type II CD23 (FC <sym> RII) molecule characterized by an affinity constant equal to or greater than 1 x 10 ^ 9 ^ Ka Mol ^ -1 ^, to the preparation of those antibodies, to pharmaceutical compositions that contain these antibodies, and their use in therapy, particularly in the treatment of autoimmune and inflammatory disorders.

BR9910327-3A 1998-05-09 1999-05-07 Antibody, use of an antibody, DNA sequence encoding an antibody chain, and, pharmaceutical formulation BR9910327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
BR9910327A true BR9910327A (en) 2001-01-30

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910327-3A BR9910327A (en) 1998-05-09 1999-05-07 Antibody, use of an antibody, DNA sequence encoding an antibody chain, and, pharmaceutical formulation

Country Status (25)

Country Link
US (1) US7008623B1 (en)
EP (1) EP1076701A1 (en)
JP (1) JP2002514421A (en)
KR (1) KR20010043470A (en)
CN (1) CN1308676A (en)
AP (1) AP1547A (en)
AU (1) AU763491B2 (en)
BR (1) BR9910327A (en)
CA (1) CA2328606A1 (en)
EA (1) EA200001041A1 (en)
EE (1) EE200000658A (en)
GB (1) GB9809839D0 (en)
HR (1) HRP20000762A2 (en)
HU (1) HUP0102005A3 (en)
ID (1) ID28088A (en)
IL (1) IL139384A0 (en)
IS (1) IS5696A (en)
NO (1) NO20005632L (en)
NZ (1) NZ507879A (en)
PL (1) PL344019A1 (en)
SK (1) SK16762000A3 (en)
TR (1) TR200003281T2 (en)
WO (1) WO1999058679A1 (en)
YU (1) YU69000A (en)
ZA (1) ZA200006312B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
MXPA06000176A (en) * 2003-12-10 2006-06-27 Millennium Pharm Inc Humanized anti-ccr2 antibodies and methods of use.
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
NZ550518A (en) 2004-03-23 2009-11-27 Biogen Idec Inc Agents that cross link TNF receptors for treating cancer
EP1799260A4 (en) * 2004-09-29 2011-09-28 Centocor Inc ANTIAMYLOIDE ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101309704B (en) 2005-11-14 2012-10-10 礼纳特神经系统科学公司 Antagonist antibodies against calcitonin gene-related peptide and methods of use thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
BRPI0819693A2 (en) 2007-11-30 2020-08-18 Glaxo Group Limited CONSTRUCTION OF ANTIGEN BINDING, METHOD FOR TREATING A PATIENT SUFFERING FROM CANCER OR AN INFLAMMATORY DISEASE, POLYNUCLEOTIDE SEQUENCE, POLYNUCLEOTIDE, HOSTED CELL, TRANSFORMED, EFFECTIVENESS, HUMAN RESOURCE
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
WO2009135853A2 (en) 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
WO2010122090A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Fgfr1c antibody combinations
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
FR2957598B1 (en) * 2010-03-17 2015-12-04 Lfb Biotechnologies NOVEL SIGNAL PEPTIDE AND USE THEREOF FOR THE PRODUCTION OF RECOMBINANT PROTEINS
SMT201800397T1 (en) 2010-11-23 2018-09-13 Glaxo Group Ltd Antigen binding proteins to oncostatin m (osm)
MX2013005847A (en) 2010-11-24 2013-12-12 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf.
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2015004038A1 (en) * 2013-07-10 2015-01-15 Onconox Aps ANTIBODIES TO β2-GLYCOPROTEIN I AND THERAPEUTIC USES THEREOF
MX378344B (en) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING THEM.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MY205096A (en) 2015-09-02 2024-10-01 Immutep Sas Anti-lag-3 antibodies
JP6935184B2 (en) * 2016-05-31 2021-09-15 シスメックス株式会社 Monoclonal antibodies that react with glycopeptides and their uses
US10479827B2 (en) * 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
PE20191148A1 (en) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh TREATMENT OF REFRACTORY MIGRANA
CN113874398B (en) 2019-05-21 2025-08-01 诺华股份有限公司 CD19 binding molecules and uses thereof
CN114222760A (en) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 IL1RAP binding proteins
CN112552403A (en) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 Fab fragment of human anti-human CD23 antibody, pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DK1266965T3 (en) * 1991-07-25 2006-09-25 Biogen Idec Inc Recombinant antibodies for human therapy
WO1996012741A1 (en) * 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
HUP0102005A3 (en) 2003-10-28
TR200003281T2 (en) 2001-03-21
IL139384A0 (en) 2001-11-25
YU69000A (en) 2003-08-29
US7008623B1 (en) 2006-03-07
AP1547A (en) 2006-01-13
ZA200006312B (en) 2003-02-26
NO20005632L (en) 2001-01-08
HUP0102005A2 (en) 2001-10-28
SK16762000A3 (en) 2001-07-10
KR20010043470A (en) 2001-05-25
WO1999058679A1 (en) 1999-11-18
ID28088A (en) 2001-05-03
HRP20000762A2 (en) 2001-06-30
PL344019A1 (en) 2001-09-24
JP2002514421A (en) 2002-05-21
IS5696A (en) 2000-10-31
NZ507879A (en) 2004-02-27
CA2328606A1 (en) 1999-11-18
GB9809839D0 (en) 1998-07-08
EP1076701A1 (en) 2001-02-21
CN1308676A (en) 2001-08-15
AU3836799A (en) 1999-11-29
AU763491B2 (en) 2003-07-24
NO20005632D0 (en) 2000-11-08
EE200000658A (en) 2002-04-15
EA200001041A1 (en) 2001-06-25
AP2000001983A0 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
BR9910327A (en) Antibody, use of an antibody, DNA sequence encoding an antibody chain, and, pharmaceutical formulation
ATE240395T1 (en) ANTIBODIES AGAINST E-SELECTIN
EP0746398A4 (en) PURIFICATION OF ANTIBODIES
BRPI0314038B8 (en) isolated human antibody, isolated nucleic acid molecule, vector, use of an antibody, and pharmaceutical composition
DE69232309D1 (en) MOSTLY PURE RECEPTOR-LIKE, TGF-BETA-1 BINDING MOLECULES AND THEIR USE
BR0305074A (en) High affinity cosmetic compositions
BR0209689A (en) Use of hmg fragment as anti-inflammatory agent
AR038568A1 (en) ANTI-A BETA ANTIBODIES AND ITS USE
UA89017C2 (en) HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B
BR9902039A (en) Binding molecule to multiple single chain antigens, their preparation and use.
EA200300441A1 (en) ASSOCIATION OF THE ANTAGONIST OF THE RECEPTOR CB1 AND SIBUTRAMINE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE TREATMENT OF OBESITY
CO5690649A2 (en) ELIMINATION OF HIGH MOLECULAR WEIGHT AGGREGATES USING HYDROXIAPATITA CHROMATOGRAPHY
CL2012001063A1 (en) Human antibody that binds to human interleukin 18 (il-18h), method of preparation, nucleic acids that are dosed, composition containing them, use in the preparation of a medicament to treat illnesses mediated by il-18h. (divisional sol. 316-01).
PT817847E (en) IL-17 RECEPTOR
EA200301159A1 (en) Cytotoxic Immunoconjugates Antibodies to CD44
BR0012569A (en) Fc fusion proteins to increase the immunogenicity of peptide and protein antigens
EA200000144A1 (en) DIRECTED CYTOLYSIS OF TARGET CELLS, AGENTS AND COMPOSITIONS CAUSING CYTOLYSIS AND CONNECTIONS THAT CAN BE USED TO RECEIVE THESE AGENTS
WO2003048207A3 (en) Anti-dota antibody
BR0312521A (en) Methods for the separation and purification of fibrinogen and at least one other protein and for the co-purification of fibrinogen and factor xiii, use of immobilized metal ion affinity chromatography, fibrinogen, pharmaceutical kit, and pharmaceutical formulations and freeze-dried fibrinogen
ATE401401T1 (en) IL-2R-ASSOCIATED POLYPEPTIDE AND DNA MOLECULES ENCODING THEREOF
ATE409045T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING SOLUBLE FCGAMMA RECEPTOR IIB
SE8702734D0 (en) MONOCLONAL ANTIBODIES TO PSEUDOMONAS AERUGINOSA FLAGELLA
ATE122895T1 (en) MONOCLONAL ANTIBODIES AGAINST THE INTERLEUKIN 2 RECEPTOR.
ES2194008T3 (en) P100 PROTEIN OF HUMAN HERPES VIRUS TYPE 6, THE CORRESPONDING DNA SEQUENCES, ITS PREPARATION AND USE.
HUP9801062A2 (en) New PKA-binding proteins and their application

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]